This listing of claims will replace all prior versions an listings of the claims in the application:

Listing of Claims:

1. (Original) Pharmaceutical compositions, comprising two or more substances of the group of α-lipoic acid and its salts and isomers, ambroxol and its salts and prodrugs and inhibitors of the angiotensin-converting enzyme (ACE), optionally together with usual pharmaceutically acceptable carriers, additives and adjuvants.

2. (Original) Pharmaceutical compositions according to claim 1, comprising a combination of α-lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs.

3. (Original) Pharmaceutical compositions according to claim 1, comprising a combination of α-lipoic acid or its salts or its isomers and of at least one inhibitor of the angiotensin-converting enzyme.

4. (Original) Pharmaceutical compositions according to claim 1, comprising a combination of ambroxol or its salts or its prodrugs and of at least one inhibitor of the angiotensin-converting enzyme.

5. (Currently amended) Pharmaceutical compositions according to ~~any of the~~ claim~~s~~ 1 ~~to 4~~, comprising a combination of α-lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs and of at least one inhibitor of the angiotensin-converting enzyme.

6. (Currently amended) Pharmaceutical compositions according to ~~any of the~~ claim~~s~~ 1 ~~to 5~~, additionally comprising one or several known carriers, adjuvants and/or additives.

7. (Currently amended) Pharmaceutical compositions according to ~~any of the~~ claim~~s~~ 1 ~~to 6~~, comprising α-lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.

8. (Currently amended) Pharmaceutical compositions according to ~~any of the~~ claim~~s~~ 1, ~~to 7~~ for an oral, buccal, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.

9. (Currently amended) Pharmaceutical compositions according to ~~any of the~~ claim~~s~~ 1, ~~to 7~~ in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

10. (Currently amended) ~~Use of~~ A method comprising utilizing the pharmaceutical compositions according to ~~one or several of the~~ claims 1, ~~to 9~~ for a prevention and a therapy of neurodegenerative diseases.

11. (Currently amended) ~~Use~~ A method according to claim 10 for a prevention and a therapy of the diseases ischemic or hemorrhagic stroke, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Hunntington's disease, multiple sclerosis, neurodegeneration of aged people, dementia, cranial cerebral trauma, and Autosomal Dominant Neurohypophyseal Diabetes Insipidus.

12. (Currently amended) ~~Use~~ A method according to claim 10 for a prevention and a therapy of cerebral ischemia resulting from cardial and cardiovascular insults.

13. (New) Pharmaceutical compositions according to claim 2, comprising a combination of α-lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs and of at least one inhibitor of the angiotensin-converting enzyme.

14. (New) Pharmaceutical compositions according to claim 3, comprising a combination of α-lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs and of at least one inhibitor of the angiotensin-converting enzyme.

15. (New) Pharmaceutical compositions according to claim 4, comprising a combination of α-lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs and of at least one inhibitor of the angiotensin-converting enzyme.

16. (New) Pharmaceutical compositions according to claim 2, additionally comprising one or several known carriers, adjuvants and/or additives.

17. (New) Pharmaceutical compositions according to claim 3, additionally comprising one or several known carriers, adjuvants and/or additives.

18. (New) Pharmaceutical compositions according to claim 4, additionally comprising one or several known carriers, adjuvants and/or additives.

19. (New) Pharmaceutical compositions according to claim 5, additionally comprising one or several known carriers, adjuvants and/or additives.

20. (New) Pharmaceutical compositions according to claim 2, comprising α-lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.

21. (New) Pharmaceutical compositions according to claim 3, comprising α-lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.

22. (New) Pharmaceutical compositions according to claim 4, comprising α-lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.

23. (New) Pharmaceutical compositions according to claim 5, comprising α-lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the

angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.

24. (New) Pharmaceutical compositions according to claim 6, comprising α-lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.

25. (New) Pharmaceutical compositions according to claim 2, for an oral, buccal, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.

26. (New) Pharmaceutical compositions according to claim 3, for an oral, buccal, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.

27. (New) Pharmaceutical compositions according to claim 4, for an oral, buccal, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.

28. (New) Pharmaceutical compositions according to claim 5, for an oral, buccal, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.

29. (New) Pharmaceutical compositions according to claim 6, for an oral, buccal, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.

30. (New) Pharmaceutical compositions according to claim 7, for an oral, buccal, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.

31. (New) Pharmaceutical compositions according to claim 2, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

32. (New) Pharmaceutical compositions according to claim 3, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

33. (New) Pharmaceutical compositions according to claim 4, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

34. (New) Pharmaceutical compositions according to claim 5, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

35. (New) Pharmaceutical compositions according to claim 6, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

36. (New) Pharmaceutical compositions according to claim 7, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

37. (New) A method comprising utilizing the pharmaceutical compositions according to claim 2 for a prevention and a therapy of neurodegenerative diseases.

38. (New) A method comprising utilizing the pharmaceutical compositions according to claim 3 for a prevention and a therapy of neurodegenerative diseases.

39. (New) A method comprising utilizing the pharmaceutical compositions according to claim 4 for a prevention and a therapy of neurodegenerative diseases.

40. (New) A method comprising utilizing the pharmaceutical compositions according to claim 5 for a prevention and a therapy of neurodegenerative diseases.

41. (New) A method comprising utilizing the pharmaceutical compositions according to claim 6 for a prevention and a therapy of neurodegenerative diseases.

42. (New) A method comprising utilizing the pharmaceutical compositions according to claim 7 for a prevention and a therapy of neurodegenerative diseases.

43. (New) A method comprising utilizing the pharmaceutical compositions according to claim 8 for a prevention and a therapy of neurodegenerative diseases.

44. (New) A method comprising utilizing the pharmaceutical compositions according to claim 9 for a prevention and a therapy of neurodegenerative diseases.

Respectfully submitted,

By: /Martin G. Linihan/
Martin G. Linihan
Reg. No. 24,926

Hodgson Russ LLP
One M&T Plaza, Suite 2000
Buffalo, New York 14203
Telephone: 716-848-1367
Dated: January 26, 2004